Celebrating 10 years of success for Infusion

As the business took off, more space was needed, and the company moved in 2009 to “real” office space just up the road in Haddam, CT, across the street from the Connecticut River, eventually employing a staff of 10 that year. A year later, in 2010, Infusion had doubled in size and became part of the UDG/Ashfield family. Infusion continued to grow at a steady pace into new therapeutic areas with more clients and employees, and in October 2016, Infusion left its country setting and moved into larger corporate offices in downtown Middletown, CT. Our staff now comprises 45 people and includes account executives, medical writers, scientific directors, medical editors, and graphic designers. Three of the four original employees still work at Infusion (Matt, Angela, and Rick Kemmerer), and many of us have been here 5+ years. It’s the challenge of the work and the quality of the people we work with that gets us into the office every day and keeps us here long-term. Some 90% of our scientific staff have advanced degrees, and our management team has 18+ years of experience in healthcare communication; our scientific team 10+ years; our core delivery team 10+ years; and client services 8+ years. Heather Sylvestro, our Director of Graphics and Production, is an award-winning designer, having been recognised several times by professional advertising/graphics industry groups for her designs and having had her design chosen as the artwork for the 2014 annual meeting of th...
Source: Ashfield Healthcare News - Category: Pharmaceuticals Authors: Tags: Ashfield Source Type: news

Related Links:

Authors: Sano A, Inoue J, Kakazu E, Ninomiya M, Iwata T, Morosawa T, Takai S, Nakamura T, Masamune A Abstract Selective immunoglobulin M deficiency (SIGMD) is an uncommon primary immunodeficiency disorder. We herein report an SIGMD patient with autoimmune hepatitis. A 21-year-old Japanese man was transferred to our hospital because of acute liver dysfunction. His serum IgM level was low, whereas those of IgG and IgA were normal, indicating that he had SIGMD. We diagnosed him with acute-onset autoimmune hepatitis, and his liver function test findings gradually recovered with corticosteroid administration. Although S...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Publication date: Available online 18 April 2019Source: Biochimica et Biophysica Acta (BBA) - Gene Regulatory MechanismsAuthor(s): Silvia Pignani, Federico Zappaterra, Elena Barbon, Antonia Follenzi, Matteo Bovolenta, Francesco Bernardi, Alessio Branchini, Mirko PinottiAbstractEngineered transcription factors (TF) have expanded our ability to modulate gene expression and hold great promise as bio-therapeutics. The first-generation TF, based on Zinc Fingers or Transcription-Activator-like Effectors (TALE), required complex and time-consuming assembly protocols, and were indeed replaced in recent years by the CRISPR activati...
Source: Biochimica et Biophysica Acta (BBA) Gene Regulatory Mechanisms - Category: Genetics & Stem Cells Source Type: research
The signaling lipid sphingosine 1-phosphate (S1P), which is abundant in lymph, guides T cell exit from lymph nodes (LN) into lymph by signaling through T cell S1P receptor 1 (S1PR1). By trapping pathogenic T cells within LN and preventing them from reaching their target tissues, drugs targeting S1PR1 have been successful in treating autoimmune diseases such as multiple sclerosis, and are being tested in dermatomyositis, psoriasis, graft versus host disease, and subacute cutaneous lupus erythematosus.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Neuro-Cutaneous Biology and Inflammation Source Type: research
Sensors, Vol. 19, Pages 1881: New ISE-Based Apparatus for Na+, K+, Cl−, pH and Transepithelial Potential Difference Real-Time Simultaneous Measurements of Ion Transport across Epithelial Cells Monolayer–Advantages and Pitfalls Sensors doi: 10.3390/s19081881 Authors: Mirosław Zając Andrzej Lewenstam Magdalena Stobiecka Krzysztof Dołowy Cystic Fibrosis (CF) is the most common fatal human genetic disease, which is caused by a defect in an anion channel protein (CFTR) that affects ion and water transport across the epithelium. We devised an apparatus to enable the measurement of concentration chang...
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
Conclusion: We concluded that atopy was detected in more than one-third of adult non-CF BR patients. This study demonstrated that non-CF BR patients might have AR; it might be important to be aware of nasal symptoms in non-CF BR patients. PMID: 30997791 [PubMed - in process]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
CONCLUSIONS: Symptoma is the first and only viable solution in this market. Large-scale studies should be conducted to further validate these results as well as to assess the actual practical performance of the symptom checkers and their ability to diagnose rare diseases. PMID: 30993374 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
Authors: Hashimoto S, Inaji M, Nariai T, Kobayashi D, Sanjo N, Yokota T, Ishii K, Taketoshi M Abstract Tumefactive multiple sclerosis (tumefactive MS) is an atypical variant of MS characterized by a large isolated demyelinating lesion. Because tumefactive MS mimics high grade astrocytoma clinically and radiologically, it is difficult to distinguish between the two using only traditional diagnostic modalities, such as routine magnetic resonance imaging. [11C] methionine positron emission tomography (MET PET) has been known as a useful diagnostic tool for glioma. However, it has not been established as a diagnostic t...
Source: Neurologia Medico-Chirurgica - Category: Neurosurgery Tags: Neurol Med Chir (Tokyo) Source Type: research
Condition:   Haemophilic Pseudotumour Intervention:   Drug: Emicizumab Sponsors:   Indiana Hemophilia &Thrombosis  Center, Inc.;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cystic Fibrosis Intervention:   Behavioral: Tele-coaching Sponsors:   Boston Children’s Hospital;   Cystic Fibrosis Foundation;   Johns Hopkins University;   University of Kansas Medical Center;   West Virginia University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cystic Fibrosis Intervention:   Drug: Denosumab Sponsor:   University of Texas Southwestern Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acromegaly | Advertising | Cancer & Oncology | Conferences | Cystic Fibrosis | Haemophilia | Hemophilia | Multiple Sclerosis | Pharmaceuticals | Politics | Primary Immunodeficiency Disease | Rare Diseases | Training | Universities & Medical Training | von Willebrand Disease